Follow The Filings

PRQR ProQR Therapeutics

ProQR Therapeutics earnings company data as of 7:59 AM ET 10/23

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS — -0.08 —
Rev — — —

Insider trades

Open-market buys and sales by PRQR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PRQR insider trades
  • $1.3M bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Daniel Anton De Boer CEO
    Buy
    $354K 200,000 shares at $1.77 +67% to stake
    Traded Jul 31 Filed Aug 3
    ↗
  2. Bart Filius Director
    Buy
    $258K 150,000 shares at $1.72 +100% to stake
    Traded Jul 17 Filed Jul 21
    ↗
  3. Daniel Anton De Boer CEO
    Buy
    $261K 150,000 shares at $1.74 +100% to stake
    Traded Jul 9 Filed Jul 13
    ↗
  4. Daniel Anton De Boer CEO
    Buy
    $239K 150,000 shares at $1.59 New stake
    Traded Jul 7 Filed Jul 8
    ↗
  5. Bart Filius Director
    Buy
    $231K 150,000 shares at $1.54 New stake
    Traded Jun 26 Filed Jun 30
    ↗

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
424B5 Filing Doc
SCHEDULE 13D/A — Filing Doc
424B5 Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
SCHEDULE 13D/A — Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
20-F Filing Doc
6-K FORM 6-K Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.